$17.78 -0.72 (-3.89%)

Cellebrite DI Ltd. Class A Ordinary Shares (CLBT)

Cellebrite DI Ltd. is a provider of digital intelligence solutions, specializing in data extraction, analysis, and management for law enforcement, intelligence agencies, and enterprise clients. Known for its technology that facilitates unlocking, decoding, and review of digital devices, the company supports investigations and cybersecurity efforts worldwide.

🚫 Cellebrite DI Ltd. Class A Ordinary Shares does not pay dividends

Company News

Cellebrite Begins Its Next Chapter
The Motley Fool • Dan Caplinger • August 14, 2025

Cellebrite reported strong Q2 2025 performance with 18% year-over-year revenue growth, exceeded earnings expectations, and appointed Tom Hogan as permanent CEO. The company remains cautiously optimistic about future business prospects and potential acquisition of Corellium.

Digital Evidence Management Market to Surpass USD 19.25B by 2032 Driven by Tech Advancements & Cybercrime | Research by SNS Insider
GlobeNewswire Inc. • Sns Insider • February 3, 2025

The Digital Evidence Management Market is growing rapidly, driven by advancements in AI, ML, and blockchain, which are enhancing the efficiency, accuracy, and security of digital evidence management systems. The market is expected to reach USD 19.25 Billion by 2032, growing at a CAGR of 11.0% from 2024 to 2032.

Cellebrite DI Ltd. (CLBT) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research • Zacks Equity Research • May 23, 2024

Cellebrite DI Ltd. (CLBT) delivered earnings and revenue surprises of 33.33% and 4.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

What 4 Analyst Ratings Have To Say About Cellebrite DI
Benzinga • Benzinga Insights • August 30, 2023

Analysts have provided the following ratings for Cellebrite DI (NASDAQ:CLBT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 These 4 analysts have an average price target of $10.25 versus the cur...

This ARK holding and pandemic star is down 77% from its peak — why one hedge fund is starting to buy it
MarketWatch • MarketWatch • January 31, 2022

Our call of the day comes from a hedge fund that has been buying beaten down Teladoc. Here's why